This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F12%3A%230000292%21RIV13-MSM-00209805/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F12%3A%230000292%21RIV13-MSM-00209805
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://www.karger.com/Article/FullText/336483
dcterms:description
Background: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. Methods: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. Results: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3–69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/ partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade 6 2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. Conclusion: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile. Background: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is metronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. Methods: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. Results: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3–69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/ partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit responded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hematological toxicity of grade 6 2, hepatotoxicity of grade 3 occurred in 8 children and grade 3 cheilitis in 16 children. Conclusion: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.
dcterms:title
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience
skos:prefLabel
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience
skos:notation
RIV/00209805:_____/12:#0000292!RIV13-MSM-00209805
n16:predkladatel
n17:ico%3A00209805
n3:aktivita
n8:V n8:I n8:P
n3:aktivity
I, P(ED1.1.00/02.0068), P(ED2.1.00/03.0101), P(LM2010004), V
n3:cisloPeriodika
5
n3:dodaniDat
n6:2013
n3:domaciTvurceVysledku
n13:6595596 n13:2486725 n13:3503216
n3:druhVysledku
n20:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
150158
n3:idVysledku
RIV/00209805:_____/12:#0000292
n3:jazykVysledku
n18:eng
n3:klicovaSlova
Children; Solid tumor; Tumor angiogenesis; Metronomic chemotherapy; Relapsed pediatric solid tumor
n3:klicoveSlovo
n12:Solid%20tumor n12:Metronomic%20chemotherapy n12:Relapsed%20pediatric%20solid%20tumor n12:Children n12:Tumor%20angiogenesis
n3:kodStatuVydavatele
CH - Švýcarská konfederace
n3:kontrolniKodProRIV
[DB082EDF67E5]
n3:nazevZdroje
Oncology
n3:obor
n10:FD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
19
n3:projekt
n9:ED1.1.00%2F02.0068 n9:ED2.1.00%2F03.0101 n9:LM2010004
n3:rokUplatneniVysledku
n6:2012
n3:svazekPeriodika
82
n3:tvurceVysledku
Valík, Dalibor Dubská, Lenka Štěrba, Jaroslav Demlová, Regina
n3:wos
000303655300001
s:issn
0030-2414
s:numberOfPages
12
n19:doi
10.1159/000336483